Study of a new imaging agent for Von Hippel-Lindau disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This trial tests a special imaging agent that targets a protein found in tumors related to Von Hippel-Lindau (VHL) disease. It may help doctors better detect and monitor these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of VHL disease with a genetic test confirming it, or have a tumor type (like certain brain, adrenal, pancreas, or kidney tumors) that needs surgery.
- You must be able to perform daily activities with some help (ECOG score 0-2).
- Women who can become pregnant need a negative pregnancy test and must use highly effective birth control for 30 days after the study drug.
- Men who can father children must use highly effective birth control for 30 days after the study drug.
- You cannot have had certain previous treatments or allergies to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers information from people with a rare condition called VHL (a genetic disorder that increases the risk of certain tumors) who are taking the drug belzutifan. It looks at how well the drug works and how safe it is over time.
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
This trial studies the natural course and management of pancreatic neuroendocrine tumors in people with von Hippel–Lindau (VHL) disease. It may help doctors better predict how these pancreatic findings change over time and how to manage them.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This trial tests an experimental drug called M1-c6v1 given through an IV for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective.
This study looks back at the health records of children with Von Hippel-Lindau disease to understand how the condition progresses and to find factors that predict long-term outcomes. It focuses on hemangioblastomas in the brain and spinal cord, which are non-cancerous tumors.
Hear when a new VHL - Von Hippel-Lindau Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.